; Vector Development and Gene Therapy
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Vector Development and Gene Therapy

VIEWS: 18 PAGES: 7

  • pg 1
									Lecture and Advanced Practical Course

Vector Development and Gene Therapy
organized by

SPP 1230

the German Society for Gene Therapy (DG-GT) and the Research Priority Program 1230 of the DFG

in cooperation with the Center for Molecular Medicine Cologne, University of Cologne

2nd - 4th September 2009 ZMMK-Research Building, Cologne, Germany

SPP 1230

Lecture and Advanced Practical Course

Vector Development and Gene Therapy
General Remarks:
Participants: • Lectures: • • • A 30 minute talk plus 10 minutes of discussion Students are expected to prepare questions to ensure a lively discussion. We will provide abstracts and literature references in advance. Students interested to participate should register by July 31, 2009 at hildegard.buening@uk-koeln.de Practical course: • We offer a limited number of traineeships. Students will visit the respective laboratories to learn specific methods or techniques complementing the theoretical course. The timetable for the practical courses will be arranged between the student(s) and the course leaders. • Students interested to participate should send their application including a letter of recommendation by July 15, 2009 at hildegard.buening@uk-koeln.de Location: ZMMK-Research Building Center for Molecular Medicine Cologne (ZMMK) University of Cologne Robert-Koch-Str. 21 50931 Cologne www.zmmk.uni-koeln.de MD and PhD students

Organizing committee: Prof. Ulrich Hengge, President DG-GT, Düsseldorf

Prof. Dr. Christopher Baum Hannover Medical School, Dept. of Experimental Haematology, Carl-Neuberg-Str. 1, OE 6960, D-30625 Hannover Email: experimental.hematology@mh-hannover.de

Prof. Dr. Michael Hallek University of Cologne Department I of Internal Medicine Center of Integrated Oncology Köln Bonn Center for Molecular Medicine Cologne (ZMMK) Kerpener Str. 62, 50937 Cologne

Prof. Dr. Martin Krönke University of Cologne Institute for Medical Microbiology, Immunology, and Hygiene Center for Molecular Medicine Cologne (ZMMK) Medical Center Goldenfelsstr. 19-21, 50935 Cologne

PD Dr. Hildegard Büning University of Cologne Department I of Internal Medicine Center for Molecular Medicine Cologne (ZMMK) Robert-Koch-Str. 21; 50931 Cologne Email: hildegard.buening@uk-koeln.de

SPP 1230

Lecture and Advanced Practical Course

Vector Development and Gene Therapy
Lecture Program: September 2nd, 2009
12.45 p.m. Welcome Hildegard Büning, Cologne, Germany 1 p.m. From bench-to-bedside: Approaches for a gene therapy of chronic lymphocytic leukemia Michael Hallek, Cologne, Germany 1.40 p.m. Gene Therapy - Basic Principles and Strategies Charles Coutelle, London, UK 2.20 p.m. What you should know about non-viral vector systems Ernst Wagner, Munich, Germany 3.00 p.m. 3.30 p.m. Coffee Break Engineering of oncolytic viruses Dirk Nettelbeck, Heidelberg, Germany 4.10 p.m. Towards cell specific gene transfer: indirect and genetic-chemical targeting approaches Florian Kreppel, Ulm, Germany 4.50 p.m. Towards cell specific gene transfer: genetic targeting approaches Michael Mühlebach, Langen, Germany and Hildegard Büning, Cologne, Germany 5.30 p.m. Get-Together

September 3rd, 2009
9 a.m. Targeted modification of the mammalian genome Toni Cathomen, Hannover, Germany 9.40 a.m. Transposons for Gene Transfer Marinee Chuah, Leuven, Belgium 10.20 a.m. Modification of transgene expression (miRNA and cell specific promoters) Bernhard Gentner, Milan, Italy 11.00 a.m. 11.30 a.m. Coffee Break How to optimize transgene expression Axel Schambach, Hannover, Germany 12.10 p.m. How to influence the intracellular fate of non-integrating vector genomes Richard Harbottle, London, UK 12.50 p.m. 2. p.m. Lunch Break Gene therapy of immune deficiencies Adrian Thrasher, London, UK 2.40 p.m. Insertional mutagenesis – detection and strategies for its avoidance Christopher Baum, Hannover, Germany

3.20 p.m.

Coffee Break

3.50 p.m.

The immune system Olaf Utermöhlen, Cologne, Germany

4.30 p.m.

Viral gene therapy and the innate immune system Elke Pogge-von Strandmann, Cologne, Germany

5.10 p.m.

In utero/neonatal gene transfer – pros and cons Simon Waddington, London, UK, and Charles Coutelle, London, UK

5.50 p.m.

Social Event

September 4th, 2009
9.00 a.m. Towards vascular gene therapy Andrew Baker, Glasgow, UK 9.40 a.m. Ethical consideration on gene and cellular therapies Monika Preuss, London, UK 10.20 a.m. Stem cells – from Dolly to IPS Ulrich Martin, Hannover, Germany 11.00 a.m 11.30 a.m. Coffee Break Nature’s anti-aging program Jens Brüning, Cologne, Germany 12.10 p.m. New strategies to fight infectious disease Dorothee von Laer, Frankfurt, Germany 12.50 p.m. 2.00 p.m. Lunch Break Suicide gene therapy Boris Fehse, Hamburg, Germany 2.40 p.m. Imaging-guided gene therapy of gliomas employing HSV-1 vectors Andreas Jacobs, Fulda and Cologne, Germany 3.20 p.m. 3.50 p.m. Coffee Break Genetic modification of T cells for the treatment of tumor and viral diseases Wolfgang Uckert, Berlin, Germany 4.30 p.m. Arming the immune system to fight cancer Hinrich Abken, Cologne, Germany 5.10 p.m. Skin gene therapy Ulrich Hengge, Düsseldorf, Germany 5.50 p.m. Concluding remarks Hildegard Büning, Cologne, Germany

Lecture and Advanced Practical Course

Vector Development and Gene Therapy
Practical Course:
Topic Adenoviral production Laboratory Stefan Kochanek / Florian Kreppel (University of Ulm, Ulm) Hildegard Büning (University of Cologne, Cologne) Dorothee von Laer (Georg-Speyer-Haus, Frankfurt) Christopher Baum (MHH, Hannover) Manfred Ogris / Ernst Wagner (University of Munich, Munich) Dirk Nettelbeck (DKFZ, Heidelberg) Christof von Kalle (DKFZ, Heidelberg) Wolfgang Uckert (MDC, Berlin) Andreas Jacobs (University of Cologne, Cologne) Toni Cathomen (MHH, Hannover) Hinrich Abken (University of Cologne, Cologne) Elke Pogge-von Strandmann (University of Cologne, Cologne) Christof von Kalle (DKFZ, Heidelberg) Number of participants 1

AAV vector production

2

Retro-/lentiviral production

1-2

Retro-/lentiviral production

2

Polymer-mediated gene transfer

2

Oncolytic Adenoviruses

1-2

Oncolysis

1

Modification of T cells

6

In vivo imaging

2

Genome integration

2

FACS/MACS sorting

2

CTL/NK cytotoxicity assays

2

Vector safety

1


								
To top